The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TEVA | +42.57% | +156.12% | +20.68% | +8,391% |
| S&P | +10.51% | +83.8% | +12.94% | +2,661% |
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.49B | 3.2% |
| Gross Profit | $2.31B | 6.5% |
| Gross Margin | 51.33% | 1.6% |
| Market Cap | $23.17B | 13.5% |
| Market Cap / Employee | $0.63M | 0.0% |
| Employees | 37K | 0.0% |
| Net Income | $436.03M | 211.5% |
| EBITDA | $1.32B | 5.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.20B | -33.6% |
| Accounts Receivable | $3.81B | 10.1% |
| Inventory | 3.3K | -16.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.05B | 2.1% |
| Short Term Debt | $24.00M | -99.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.76% | 4.0% |
| Return On Invested Capital | -5.88% | -1.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$53.05M | -106.0% |
| Operating Free Cash Flow | $83.77M | -91.9% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 32.99 | - | |||
| Price to Book | 4.12 | 3.24 | 3.07 | 3.39 | 5.71% |
| Price to Sales | 1.50 | 1.07 | 1.16 | 1.39 | 15.45% |
| Price to Tangible Book Value | -1.69 | -1.23 | -1.43 | -1.75 | 28.20% |
| Price to Free Cash Flow TTM | 12.24 | 8.55 | 16.38 | 93.61 | 1156.25% |
| Enterprise Value to EBITDA | 34.49 | 35.81 | 28.86 | 29.06 | -0.48% |
| Free Cash Flow Yield | 8.2% | 11.7% | 6.1% | 1.1% | -92.04% |
| Return on Equity | -25.5% | -19.0% | -2.4% | 10.8% | -173.37% |
| Total Debt | $18.17B | $16.94B | $17.52B | $17.07B | -11.42% |
TEVA earnings call for the period ending December 31, 2024.
TEVA earnings call for the period ending September 30, 2024.
TEVA earnings call for the period ending June 30, 2024.
TEVA earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
